HSA — authorised 5 October 2018
- Marketing authorisation holder: LEADIANT BIOSCI INC
- Status: likely_approved
HSA authorised Revcovi on 5 October 2018
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. HSA authorised it on 5 October 2018.
LEADIANT BIOSCI INC holds the Singaporean marketing authorisation.